The global regenerative medicine market was estimated to be over US$ 13 billion in 2019. It is anticipated to grow at a CAGR of 23.2%from 2019 to 2030.
The significant growth of the market can be attributed to increasing prevalence of chronic as well as genetic disorders followed by increasing demand of medicines and therapies that can help cure and prevent these disorders. Moreover, increasing private and government investments for research & development of regenerative medicines are anticipated to boost the regenerative medicine market over the forecast period. To obtain better insights regarding the market scenario, prominent players are increasingly focusing on mergers, acquisitions or collaborations with smaller regenerative medicine companies. For instance, in Jan 2020, Amgen announced a strategic collaboration with BeiGene a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer. This strategic collaboration will enable Amgen to expand its oncology presence in China.
No comments:
Post a Comment